Acute stroke services in New Zealand

AIMS: To obtain an overall picture of the organisation of acute stroke management in hospitals throughout New Zealand. METHODS: A questionnaire was sent to all New Zealand hospitals. The survey included questions about access to organised stroke care, the presence of designated areas for stroke patient management, guidelines for stroke management and audit. RESULTS: Responses were received from all hospitals surveyed, with 41 admitting stroke patients acutely. Five hospitals (four regional and one large urban) had organised inpatient care. Five hospitals (three regional and two large urban) had stroke physicians. Only 40-60% of the New Zealand population had access to hospitals with guidelines for the management of complications following stroke or secondary prevention. Only fifteen of 41 hospitals had audited local stroke care. There were few differences in the management of stroke patients between urban and regional centres, but care in some regional hospitals was 'better' than that in most large urban hospitals. CONCLUSIONS: The development of an organised approach to inpatient stroke care in New Zealand and the training of general physcians, geriatricans and neurologists in stroke medicine must be seen as a priority.     

Social class mortality differences in Maori and non-Maori men aged 15-64 during the last two decades

AIMS: This investigation uses data from 1996-97 to update previous studies of social class mortality differences in Maori and non-Maori New Zealand men aged 15-64 years. METHODS: Numerator data were obtained from the national death registrations and denominator data were from the 1976, 1986 and 1996 censi. For each social class, age standardised death rates in Maori and non-Maori men were calculated for amenable, non-amenable and all causes of mortality. RESULTS: Maori male mortality was significantly higher than non-Maori mortality in each social class and for the total population for amenable (overall RR = 5.3(CI = 4.0-6.9)), non-amenable (overall RR = 2.4(2.2-2.6)) and all causes of mortality (overall RR = 2.4(2.3-2.6)). The social class mortality differences within Maori (relative index of inequality was 3.3) were markedly greater than non-Maori class differences (RII = 1.5). CONCLUSIONS: The persistently high Maori mortality rates, when controlled for social class, indicate that the poor state of Maori health cannot be explained solely by relative socioeconomic disadvantage. The high Maori rate of potentially preventable deaths indicates that the health sector is still not meeting the serious health needs of many Maori. The social class mortality gradient within Maori underlines the need to address disparities within Maori.     

Socio-economic factors and mortality among 25-64 year olds followed from 1991 to 1994: the New Zealand Census-Mortality Study

AIM: To measure the association of income, education, occupational class, small area socio-economic deprivation, car access and labour force status with mortality among 25-64 year old males and females using the 1991 census-cohort of the New Zealand Census-Mortality Study. METHODS: Mortality records for 1991-94 were anonymously and probabilistically linked to 1991 census records, thereby creating a cohort study of all New Zealand census respondents. Odds ratios of mortality comparing categories of each socio-economic factor were calculated using logistic regression. For income, education and deprivation (NZDep91) a modified relative index of inequality (RII(10:90)) was calculated. The RII(10:90) estimates the relative risk of mortality for low socio-economic people (10th percentile rank) compared to high socio-economic people (90 percentile rank) allowing direct comparisons across socio-economic factors. RESULTS: The relative risk of all-cause mortality for 25-64 year old males with an equivalised household income less than $20,000, compared to greater than $50,000, was 2.16 (95% confidence interval 1.99 to 2.34). For females, this relative risk was 1.68 (1.52 to 1.86). Using the RII(10:90) all-cause mortality was 2.22, 1.94 and 1.58 times greater among low compared to high socio-economic males for income, NZDep91 and education, respectively. For females, these RII(10:90) estimates were 1.77, 1.69 and 1.57, respectively. By cause of death, the strongest gradients were observed for respiratory diseases, followed by lung cancer, cardiovascular disease and unintentional injury. For suicide deaths, unemployed males and females had 2.70 (1.84 to 3.95) and 2.86 (1.19 to 6.85) greater rates than the employed. CONCLUSIONS: There are strong socio-economic gradients for all-cause mortality and most specific causes of mortality among both males and female adults in New Zealand, regardless of the choice of socio-economic factor. The gradients were strongest for income, followed by small area deprivation and education, and strongest for 'preventable' causes of death.     

Single-dose pharmacokinetics of nizatidine (Axid) in children

The pharmacokinetics of nizatidine following a single 5.0 mg/kg oral dose given as an extemporaneous liquid formulation in apple juice was examined in 12 healthy children (8.0 +/- 2.4 years, 30.7 +/- 8.4 kg). Nizatidine and N-desmethylnizatidine were quantitated by HPLC/MS from five post dose blood samples taken over a 12-hour period. The apparent terminal elimination rate constant for nizatidine in the pediatric subjects (0.58 +/- 0.8h(-1)) was virtually identical to that (0.54 +/- 0.13 h(-1)) previously reported from adult studies. When corrected for an estimated 30% reduction in nizatidine oral bioavailability observed in adults upon coingestion of the drug with other fruit/vegetable juices, nizatidine pharmacokinetic parameter estimates (e.g., Cmax, CL/F, Vss/F) in our pediatric subjects were similar to those previously reported in adults who were administered dimensionally similar (e.g., approximately 4 mg/kg) solid oral doses of the drug. Examination of the mean area under the curve (i.e., AUC0-infinity for nizatidine and N-desmethylnizatidine suggested an approximate 15% metabolic conversion of the parent drug. Finally, nizatidine plasma concentrations in pediatric patients following a single 5.0 mg/kg oral dose exceeded the EC50 value of the drug for gastric acid suppression determined from adult studies for approximately 6 hours.     

Novel high energy intermediate analogues with triazasterol-related structures as inhibitors of ergosterol biosynthesis. Part I: synthesis and antifungal activity of N-alkyl-N'-(phenethyl- and cyclohexenylethyl)guanidines and N2-substituted 2-imidazolinamines

A series of N-alkyl-N'-(phenethyl- and cyclohexenylethyl) guanidines and N(2)- and N(2), 4-substituted imidazolin-2-amine hydrochlorides with triazasterol-related structures was designed and synthesized as stable analogues to mimic high energy intermediates of ergosterol biosynthesis. The in vitro antifungal susceptibility tests with a standard panel of pathogenic fungi revealed moderate to strong antimycotic effects of the sixteen prepared compounds, in some cases comparable with the activity observed for itraconazole.